High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer
- PMID: 23574787
- DOI: 10.1016/j.humpath.2013.01.014
High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer
Abstract
A prognostic value for tumor-associated macrophages (TAMs) and tumor-infiltrating dendritic cells (TIDCs) has been reported in many human cancers. The objective of this study is to determine the prognostic value of CD83(+) mature TIDCs and CD68(+) TAMs in non-muscle-invasive bladder cancer at first diagnosis. Immunohistochemistry staining was performed with anti-CD68 and anti-CD83 monoclonal antibodies on tissue sections from 93 formalin-fixed, paraffin-embedded tissue blocks from pTa and pT1 bladder tumors. A scoring index based on the average density of observed positive cells in the papillary axis, the stroma, lymphoid aggregates, and into tumor foci was calculated for each patient. Comparison of baseline characteristics with marker levels was done using Pearson χ(2) or Fisher exact test. Kaplan-Meier analyses and Cox regression models were fitted to evaluate the prognostic value of TIDCs and TAMs. The absence of both CD68(+) TAMs and CD83(+) TIDCs was associated with tumor recurrence. The presence of TIDCs was associated with a significant risk of progression to muscle-invasive cancer (hazard ratio, 8.253; P = .0179). Patients were risk stratified using age and TIDC score. Patients 70 years or older with a high score of TIDCs had a 56% progression-free survival after 6 years compared with 94% for patients younger than 70 years with a low score of TIDCs. None of 20 patients with a low score of TAMs progressed. These data indicate that the presence of mature TIDCs and possibly TAMs may help risk-stratify patients at the time of first diagnosis of non-muscle-invasive bladder cancer and may be useful in tailoring follow-up and treatment strategies.
Keywords: BCG; Bacillus Calmette-Guérin; CI; CIS; DC; Dendritic cells; EORTC; European Organization for Research and Treatment of Cancer; HR; Macrophages; Non–muscle-invasive bladder cancer; Prognostic; TAM; TIDC; TUR; Tumor infiltration; carcinoma in situ; confidence interval; dendritic cells; hazard ratio; transurethral resection; tumor-associated macrophage; tumor-infiltrating dendritic cells.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.Eur Urol. 2009 Jun;55(6):1386-95. doi: 10.1016/j.eururo.2009.01.040. Epub 2009 Feb 3. Eur Urol. 2009. PMID: 19193487
-
Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.Ultrastruct Pathol. 2013 Feb;37(1):56-61. doi: 10.3109/01913123.2012.728688. Ultrastruct Pathol. 2013. PMID: 23383616
-
Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.Urol Oncol. 2014 Aug;32(6):791-7. doi: 10.1016/j.urolonc.2014.02.007. Epub 2014 Apr 29. Urol Oncol. 2014. PMID: 24794251
-
A Review of Outcomes for Stage Ta Bladder Tumors.Am J Clin Pathol. 2016 Aug;146(2):215-20. doi: 10.1093/ajcp/aqw103. Am J Clin Pathol. 2016. PMID: 27473739 Review.
-
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.World J Urol. 2020 Jun;38(6):1437-1449. doi: 10.1007/s00345-019-02936-y. Epub 2019 Sep 6. World J Urol. 2020. PMID: 31493109 Free PMC article.
Cited by
-
Immune therapies in non-muscle invasive bladder cancer.Curr Treat Options Oncol. 2015 Feb;16(2):5. doi: 10.1007/s11864-014-0315-3. Curr Treat Options Oncol. 2015. PMID: 25757877 Review.
-
Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer.Oncoimmunology. 2018 Aug 1;7(9):e1474317. doi: 10.1080/2162402X.2018.1474317. eCollection 2018. Oncoimmunology. 2018. PMID: 30393586 Free PMC article.
-
Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment.Eur Urol Open Sci. 2022 Jul 26;43:35-44. doi: 10.1016/j.euros.2022.06.007. eCollection 2022 Sep. Eur Urol Open Sci. 2022. PMID: 36246841 Free PMC article.
-
Exploring the Immunoresponse in Bladder Cancer Immunotherapy.Cells. 2024 Nov 22;13(23):1937. doi: 10.3390/cells13231937. Cells. 2024. PMID: 39682686 Free PMC article. Review.
-
Chronic inflammation in urothelial bladder cancer.Virchows Arch. 2015 Dec;467(6):623-633. doi: 10.1007/s00428-015-1820-x. Epub 2015 Aug 12. Virchows Arch. 2015. PMID: 26263854
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical